0940 GMT - Bayer's fourth-quarter results beat sales and Ebitda expectations, Morgan Stanley analysts write. However, guidance came broadly in line, so limited changes to consensus estimates are expected, they add. By division, 2025 crop science and pharma guidance implies around 2% and 4% downside risk to divisional consensus Ebitda estimates, respectively, they say. There was limited updates on litigation, with Bayer confirming that it will file a petition for review with the U.S. Supreme Court on glyphosate claims. Meanwhile, a ruling from the Washington Supreme Court for the Erickson case--which relates to claims of personal injury related to alleged PCB exposure--is expected in the coming months. Shares rise 5.3%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 05, 2025 04:40 ET (09:40 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.